Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study
Authors
Yao, JFazio, N
Singh, S
Buzzoni, R
Carnaghi, C
Wolin, E
Tomasek, J
Raderer, M
Lahner, H
Voi, M
Pacaud, L
Rouyrre, N
Sachs, C
Valle, Juan W
Delle Fave, G
Van Cutsem, E
Tesselaar, M
Shimada, Y
Oh, D
Strosberg, J
Kulke, M
Pavel, M
Affiliation
MD Anderson Cancer Center, University of Texas, HoustonIssue Date
2016